Tags |
|
|
Links |
|
|
Digg It - Chapter 7 Bankruptcy
Chapter 7 is the most common form of bankruptcy in the United States. Chapter 7 refers to the numbe
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
r of a chapter in the Bankruptcy Code that lists the rules and regulations to be followed during li
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
quidation proceedings. Very simply put, when business files for Chapter 7, it means that the organi
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
zation intends to sell all its property and use the money to pay off its creditors. The business wi
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
l then cease functioning.
When the money is distributed to the creditors, secured creditors like b
When the money is distributed to the creditors, secured creditors like b
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
ondholders get first priority. Unsecured creditors like vendors who have not been paid for the prod
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
ucts delivered to the company are given a lower priority.
This law is slightly different when it c
This law is slightly different when it c
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
omes to individuals. When individuals file for Chapter 7, they are allowed to hold certain pieces o
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
property that are exempt and most liens, like mortgaged property for example, are allowed to be re
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
tained by the individual.
In both personal and business bankruptcy, other property and assets are
In both personal and business bankruptcy, other property and assets are
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
sold by an interim trustee and the money is given to the creditors. Many kinds of unsecured debt ar
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
e cancelled. However, there are exceptions like child support, student loans, most taxes, and fines
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
imposed by any court for crimes committed the person will still be responsible for these debts, eve
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
n after filing for bankruptcy.
This differs from the Chapter 7 filed by an organization. The organ
This differs from the Chapter 7 filed by an organization. The organ
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
ization is not granted a discharge of its debts under any circumstances. Once all the assets have b
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
een sold and the money distributed among the creditors, if there are still outstanding payments to
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
e made, these debts continue to exist, atleast theoretically.
One of the major disadvantages of fi
One of the major disadvantages of fi
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
ling for Chapter 7 is that it stays on the person's or organization's credit report for 10 years. T
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
his makes acquiring credit more difficult, and whatever credit is obtained will be at less than fav
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
orable terms. Bankruptcy serverly harms chances the individual may have of obtaining future credit
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.diggit.org.ua/article/90854/diggit-Chapter-7-Bankruptcy.html">Chapter 7 Bankruptcy</a>
BB link (for phorums):
[url=http://www.diggit.org.ua/article/90854/diggit-Chapter-7-Bankruptcy.html]Chapter 7 Bankruptcy[/url]
Related Articles:
Strategic Planning One Answer to Beating Your Competition
Bookmark it:
|